As shown in Figure 1, the most frequently prescribed drugs in T2D-HCV+ patients were agents acting on the renin–angiotensin system (untreated vs. DAA-treated: 58.8% vs. 63.5%, p = 0.100) followed by drugs for acid-related disorders (untreated vs. DAA-treated: 52.9% vs. 63.9%, p < 0.001) and antibacterials for systemic use (untreated vs. DAA-treated: 52.5% vs. 62.9%, p < 0.001). This evidence concerns the gene REN and type 2 diabetes mellitus.